Judge William Zloch hears sentencing argument by public defender for McDanielOGE Fonn 278 (March 2014)
1 duplicate copy in the archive
LinkedIn post on Regeneron’s Praluent pricing and market rollout
Title Matchkaggle-ho-025890
Case Filed-34218House OversightLinkedIn post on Regeneron’s Praluent pricing and market rollout
November 11, 20252p1 persons
Case File
d-34218House OversightLinkedIn post on Regeneron’s Praluent pricing and market rollout
Financial Record
The passage discusses drug pricing, market expectations, and physician usage surveys for Praluent. It contains no concrete allegations, financial flows, or links to high‑profile political or intellige Regeneron CEO Leonard Schleifer comments on pricing and access. Praluent price is 46% higher than analyst forecasts. Physician survey suggests broader off‑label use than label.
Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #025890
Pages
2
Persons
1
Integrity
No Hash Available
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.